These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2342544)

  • 21. [Acute brain syndrome after mefloquine treatment].
    Rønn AM; Bygbjerg IC
    Ugeskr Laeger; 1994 Oct; 156(41):6044-5. PubMed ID: 7992450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute psychosis after mefloquine. Report of six cases.
    Sowunmi A; Adio RA; Oduola AM; Ogundahunsi OA; Salako LA
    Trop Geogr Med; 1995; 47(4):179-80. PubMed ID: 8560592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Mood disorder after malaria prophylaxis with mefloquine (two case reports)].
    Oueriagli Nabih F; Touhami M; Laffinti A; Abilkacem L
    Encephale; 2011 Oct; 37(5):393-6. PubMed ID: 22032283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers.
    Barrett PJ; Emmins PD; Clarke PD; Bradley DJ
    BMJ; 1996 Aug; 313(7056):525-8. PubMed ID: 8789977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine.
    van Riemsdijk MM; Sturkenboom MC; Ditters JM; Tulen JH; Ligthelm RJ; Overbosch D; Stricker BH
    Br J Clin Pharmacol; 2004 Apr; 57(4):506-12. PubMed ID: 15025750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mefloquine for multidrug-resistant malaria.
    Luxemburger C; Nosten F; ter Kuiile F; Frejacques L; Chongsuphajaisiddhi T; White NJ
    Lancet; 1991 Nov; 338(8777):1268. PubMed ID: 1682659
    [No Abstract]   [Full Text] [Related]  

  • 27. Neurologic reactions after a therapeutic dose of mefloquine.
    Patchen LC; Campbell CC; Williams SB
    N Engl J Med; 1989 Nov; 321(20):1415-6. PubMed ID: 2811953
    [No Abstract]   [Full Text] [Related]  

  • 28. [Encephalopathy and memory disorders during treatments with mefloquine].
    Marsepoil T; Petithory J; Faucher JM; Ho P; Viriot E; Benaiche F
    Rev Med Interne; 1993; 14(8):788-91. PubMed ID: 8191092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mefloquine and scuba diving.
    Wright D
    N Z Med J; 1995 Dec; 108(1013):514. PubMed ID: 8532239
    [No Abstract]   [Full Text] [Related]  

  • 30. [Neuropsychiatric symptoms in preventive antimalarial treatment with mefloquine: apropos of 2 cases].
    Lebain P; Juliard C; Davy JP; Dollfus S
    Encephale; 2000; 26(4):67-70. PubMed ID: 11064842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Mefloquine: neuropsychiatric adverse effects are often severe and persistent long after withdrawal of the drug].
    Jensen JJ
    Ugeskr Laeger; 1998 Apr; 160(16):2413. PubMed ID: 9616091
    [No Abstract]   [Full Text] [Related]  

  • 32. Neuropsychiatric events and travel: do antimalarials play a role?
    Schlagenhauf P; Steffen R
    J Travel Med; 2000; 7(5):225-6. PubMed ID: 11231204
    [No Abstract]   [Full Text] [Related]  

  • 33. Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions.
    Bem JL; Kerr L; Stuerchler D
    J Trop Med Hyg; 1992 Jun; 95(3):167-79. PubMed ID: 1597872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Mefloquine-induced psychoses--problems in etiologic classification based on 2 case reports].
    Hollweg M; Soyka M; Greil W
    Psychiatr Prax; 1995 Jan; 22(1):33-6. PubMed ID: 7892342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Mefloquine and sulfadoxine/pyrimethamine overdose in malaria tropica].
    Burgmann H; Winkler S; Uhl F; Feucht M; Hellgren U; Bergqvist Y; Feistauer S; Breyer S; Graninger W
    Wien Klin Wochenschr; 1993; 105(2):61-3. PubMed ID: 8442357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse reactions.
    Eaton L
    Nurs Times; 1996 Jun 12-8; 92(24):16-7. PubMed ID: 8716185
    [No Abstract]   [Full Text] [Related]  

  • 37. Mefloquine: contraindicated in patients with mood, psychotic or seizure disorders.
    Wooltorton E
    CMAJ; 2002 Nov; 167(10):1147. PubMed ID: 12427708
    [No Abstract]   [Full Text] [Related]  

  • 38. Acute and long-term psychiatric side effects of mefloquine: a follow-up on Danish adverse event reports.
    Ringqvist Å; Bech P; Glenthøj B; Petersen E
    Travel Med Infect Dis; 2015; 13(1):80-8. PubMed ID: 25435322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Neuropsychic side-effects of therapeutic doses of zipeprol]].
    Lauby V; Imbert B; Eysseric H; Dufrêne I; Mallaret M
    Rev Med Interne; 1995; 16(3):212-3. PubMed ID: 7740233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Mental alterations as side-effects of oral contraceptives].
    Payk TR
    Fortschr Neurol Psychiatr Grenzgeb; 1972 Apr; 41(4):225-35. PubMed ID: 4488436
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.